Investors should monitor mid-2026 data readouts for OPGx-BEST1 and LCA5, as well as the October 2026 PDUFA decision for Phentolamine. While financials improved, the company remains dependent on clinical milestones and future financing.
Price Chart
Executive Summary
Opus Genetics reported financial results for 2025, highlighting a reduced net loss, increased cash runway to mid-2028 following a $25M private placement, and progress across its gene therapy pipeline including positive early clinical data for OPGx-BEST1 and an October 2026 PDUFA date for Phentolamine Ophthalmic Solution. Revenue from collaborations rose to $14.2M, though the company remains pre-revenue with no product sales.
Key Financial Metrics
Key Facts
- Cash and cash equivalents were $45.1M as of Dec 31, 2025; raised $25M post-quarter, extending cash runway into H1 2028
- License and collaboration revenue increased to $14.2M in 2025 from $11.0M in 2024, driven by Viatris R&D reimbursement
- Net loss narrowed to $49.6M ($0.80/share) from $57.5M ($2.15/share) in 2024, primarily due to absence of $28M in-process R&D charge in 2024
- R&D expenses rose to $30.8M from $26.9M; G&A increased to $22.0M from $18.2M
- OPGx-BEST1 showed early safety and vision improvement signals in a sentinel patient, with full Cohort 1 data expected mid-2026
- FDA set PDUFA date of October 17, 2026 for Phentolamine Ophthalmic Solution 0.75% for presbyopia
- Funding secured from Abu Dhabi’s Healthcare Research and Innovation Fund for OPGx-MERTK trial
Financial Impact
Cash runway extended to mid-2028 due to $70.1M aggregate cash; revenue up 29% YoY to $14.2M but still from collaborations only; net loss decreased by $7.9M
Risk Factors
- High cash burn: R&D and G&A expenses continue to rise, increasing future funding needs
- Clinical-stage risk: Pipeline is early with no approved products; trial setbacks could significantly impact valuation
- Dilution risk: $11.5M increase in fair value of warrant liabilities may lead to future share issuance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252597 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 144 | $3.52 | awaiting T+60 | — | $3.32 (−5.68%) |
Oct 21, 2026 5d ago | 8-K | $3.82 | awaiting T+60 | — | $3.32 (−13.09%) |
Oct 15, 2026 11d ago | 8-K | $3.84 | awaiting T+60 | — | $3.32 (−13.54%) |
Oct 15, 2026 11d ago | Press Release | $3.84 | awaiting T+60 | — | $3.32 (−13.54%) |
Sep 22, 2026 4w ago | Institutional Cluster | $5.16 | awaiting T+60 | — | $3.32 (−35.66%) |
Sep 11, 2026 6w ago | 8-K | $6.04 | awaiting T+60 | — | $3.32 (−45.03%) |
Sep 9, 2026 6w ago | 8-K | $5.73 | awaiting T+60 | — | $3.32 (−42.06%) |
Sep 2, 2026 7w ago | Press Release | $4.45 | awaiting T+60 | — | $3.32 (−25.39%) |
Aug 6, 2026 11w ago | 8-K | $3.72 | awaiting T+60 | — | $3.32 (−10.75%) |
Jul 23, 2026 13w ago | 144 | $2.92 $4.05 | ▲ +38.70% | ▲ +34.15% | $3.32 (+13.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers